SpringWorks Therapeutics (SWTX) has announced its preliminary net product revenues for the fourth quarter and full-year 2024 for its drug Ogsiveo, alongside outlining expected milestones for 2025. Despite the announcement, SWTX's stock experienced a decline.
The FDA has approved Gomekli (mirdametinib) for both adult and pediatric patients with Neurofibromatosis Type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
SpringWorks Therapeutics reported $49.3 million in OGSIVEO® (nirogacestat) net product revenue for the third quarter of 2024, marking a 23% increase over the previous quarter.
SpringWorks Therapeutics' OGSIVEO generated significant revenue, with $49.3 million in Q3 2024 and $130.0 million for the first nine months, following its FDA approval for desmoid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.